Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Longterm outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy.-MedSci.cn

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Longterm outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy.

Perez-Valderrama, B; Powles, T; Sridhar, SS; Caserta, C; Loriot, Y; Gupta, S; Bellmunt, J; Sternberg, CN; Wang, J; Costa, N; Laliberte, RJ; Di Pietro, A; Park, SH; Grivas, P

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (16):

科室
- - 订阅+
  - 更多科室
工具
服务